Helios - For the fiscal year ending December 2024, significant revenue growth is expected, and research and development will be promoted in the fields of somatic stem cell regenerative Pharmaceuticals and iPSC regenerative Pharmaceuticals.

Helios <4593> announced its consolidated financial results (IFRS) for the fiscal year ending December 2024 on the 14th.

Fisco JapanFeb 17 01:09 ET

Alfressa HD, MonotaRO, etc. (additional) Rating

Downgrade - Bearish Code Stock Name Securities Company Previous Change After ------------------------------------------------------------ <3659> Nexon Macquarie "Outperform" "Neutral" <6273> SMC Macquarie "Outperform" "Neutral" <6841> Yokogawa Electric Daiwa "2" "3" Target Price Change Code Stock Name Securities Company Previous Change After --------------------

Fisco JapanFeb 16 21:30 ET

Rating information (Target Price change - Part 1) = Ship HD, Astellas Pharma, ETC.

Nomura Securities (three-tier: Buy > neutral > Reduce) Ship HD <3360.T> ―― "Buy" → "Buy", 3,430 yen → 3,150 yen Miura Industries <6005.T> ―― "Buy" → "Buy", 5,200 yen → 4,700 yen Sysmex <6869.T> ―― "Buy" → "Buy", 3,800 yen → 3,900 yen NX HD <9147.T> ―― "Buy" → "Buy", 2,933 yen → 3,500 yen Alfresa <2784.T> ―― "neutral".

Kabushiki ShimbunFeb 16 19:52 ET

Express News | Reported Earlier, U.S. FDA Grants Expanded Label For Astellas' IZERVAY, Allowing Long-Term Treatment For Geographic Atrophy

BenzingaFeb 13 01:23 ET

Astellas Pharma : FDA Approves Expanded Label For IZERVAY For Geographic Atrophy

RTTNewsFeb 12 22:38 ET

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

BenzingaFeb 11 14:13 ET